Opportunity Information: Apply for RFA CA 23 025
The National Institutes of Health (NIH) funding opportunity titled "Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)" (Funding Opportunity Number RFA-CA-23-025) is a discretionary grant program offered through a cooperative agreement mechanism (U01). Its central goal is to fund the development and rigorous testing of interventions at the primary care practice level and the broader health system level that can improve the quality of care for adult cancer survivors during active treatment and/or after treatment ends. Because this is a U01 cooperative agreement, awardees should expect substantial NIH involvement during the project, typically including coordination, milestone-driven progress, and collaboration expectations that go beyond a standard investigator-initiated grant. The opportunity is also explicitly structured around clinical trial activity, meaning applicants are expected to design and carry out a study that meets NIH's definition of a clinical trial.
The focus of the program is practical and implementation-oriented: it is aimed at strategies that help primary care settings and health systems better support adult cancer survivors as they transition between oncology and primary care, manage ongoing and late effects of cancer and its treatment, and receive comprehensive, high-quality survivorship care. In real-world terms, this could include improving care coordination between oncologists and primary care clinicians, strengthening survivorship care planning and follow-up workflows, integrating evidence-based screening and management for recurrence risk and secondary cancers, addressing chronic conditions that may be complicated by cancer therapies, and improving systems for monitoring symptoms, mental health, and quality of life. The intent is to move beyond describing survivorship care gaps and instead build and test interventions that can function in routine primary care and health system environments.
A key theme embedded in the announcement is that survivorship care is not solely an oncology responsibility; adult survivors often rely heavily on primary care for long-term management, preventive care, and navigation of complex health needs. This RFA supports interventions that can be implemented where survivors actually receive ongoing care, including community-based primary care practices, integrated delivery systems, and other real-world clinical settings. Projects that address system-level barriers, such as fragmented records, unclear roles across specialties, limited time in visits, inadequate reimbursement structures, or lack of survivorship-specific clinical decision support, align with the spirit of a practice- and health system-level intervention emphasis.
In terms of eligibility, the opportunity is broadly open to a wide range of U.S.-based organizations. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized); Native American tribal organizations (other than federally recognized tribal governments); public housing authorities and Indian housing authorities; nonprofits with 501(c)(3) status (and nonprofits without 501(c)(3) status), both outside higher education; for-profit organizations other than small businesses; and small businesses. The announcement also highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and Indian/Native American tribal governments that are not federally recognized.
The geographic and foreign participation rules are strict. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply. In addition, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. Practically, that means the applicant organization must be U.S.-based and the funded work must be structured without foreign components under NIH policy.
The award information included in the source indicates an award ceiling of $750,000. The original closing date listed for the opportunity was 2023-07-24, and the posting creation date is 2023-03-09. The program is associated with CFDA number 93.393 and falls under the broad activity category of Education and Health. Even though the original due date has passed, the details remain useful as a template for similar NIH survivorship, primary care, and implementation-focused opportunities, especially those using cooperative agreements and requiring clinical trial designs.
Overall, this funding opportunity is designed for teams that can bridge oncology, primary care, and health services research to build interventions that work at the level of practice workflows and health system operations, then test those interventions in a way that produces solid evidence about effectiveness, feasibility, and potential for broader adoption in routine care for adult cancer survivors.Apply for RFA CA 23 025
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393.
- This funding opportunity was created on 2023-03-09.
- Applicants must submit their applications by 2023-07-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $750,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required) - RFA-CA-23-025
What is the name of this NIH funding opportunity?
The opportunity is titled "Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)" and is offered by the National Institutes of Health (NIH).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-CA-23-025.
What type of funding mechanism is used?
This is a cooperative agreement using the U01 mechanism. That means NIH expects to be substantially involved in the project during the award period, beyond what is typical for many investigator-initiated grants.
What does "cooperative agreement" (U01) mean for awardees?
Because this is a U01, awardees should expect substantial NIH involvement during the project. The opportunity description specifically notes coordination, milestone-driven progress, and collaboration expectations that go beyond a standard grant.
Is a clinical trial required?
Yes. The opportunity is explicitly structured around clinical trial activity. Applicants are expected to design and carry out a study that meets NIH's definition of a clinical trial.
What is the main purpose of this program?
The central goal is to fund the development and rigorous testing of interventions at the primary care practice level and the broader health system level to improve quality of care for adult cancer survivors during active treatment and/or after treatment ends.
Who is the target population?
The focus is on adult cancer survivors, including those who are in active treatment and those who have completed treatment.
What kinds of interventions does NIH want to support through this RFA?
The emphasis is on practical, implementation-oriented interventions that can function in routine primary care and health system environments. Interventions should be designed to improve survivorship care where survivors actually receive ongoing care.
At what levels should interventions be designed?
Interventions are intended to operate at the primary care practice level and/or at the broader health system level (for example, changes to workflows, coordination processes, or system operations).
What are examples of focus areas that fit the intent of the RFA?
Examples described include improving care coordination between oncology and primary care clinicians, strengthening survivorship care planning and follow-up workflows, integrating evidence-based screening and management for recurrence risk and secondary cancers, addressing chronic conditions complicated by cancer therapies, and improving systems for monitoring symptoms, mental health, and quality of life.
Does the RFA emphasize describing care gaps or building solutions?
The intent is to move beyond describing survivorship care gaps and instead build and test interventions that can work in real-world primary care and health system settings.
Is survivorship care treated as only an oncology responsibility?
No. A key theme is that survivorship care is not solely an oncology responsibility. Adult survivors often rely on primary care for long-term management, preventive care, and navigation of complex health needs.
What clinical settings are considered relevant for proposed projects?
The opportunity aligns with interventions that can be implemented in community-based primary care practices, integrated delivery systems, and other real-world clinical settings where adult cancer survivors receive ongoing care.
What system-level barriers are specifically called out as relevant?
The description highlights barriers such as fragmented records, unclear roles across specialties, limited time in visits, inadequate reimbursement structures, and lack of survivorship-specific clinical decision support.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organization types, such as state/county/city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations (other than federally recognized tribal governments); public housing authorities and Indian housing authorities; nonprofits (with and without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses.
Are specific institution types or community organizations mentioned as eligible?
Yes. The announcement highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and Indian/Native American tribal governments that are not federally recognized.
Can foreign organizations apply?
No. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply.
Can a U.S. organization include a foreign component?
No. Non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
What does the foreign participation restriction mean in practical terms?
Practically, the applicant organization must be U.S.-based and the funded work must be structured without foreign components under NIH policy.
What is the award ceiling listed in the opportunity summary?
The award ceiling listed is $750,000.
What is the CFDA number associated with this program?
The program is associated with CFDA number 93.393.
What broad activity category is this opportunity associated with?
It falls under the broad activity category of Education and Health.
When was the opportunity posted, and what was the original closing date?
The posting creation date is 2023-03-09, and the original closing date listed was 2023-07-24.
If the due date has passed, is the information still useful?
Yes. Even though the original due date has passed, the details can still serve as a template for similar NIH survivorship, primary care, and implementation-focused opportunities, especially those using cooperative agreements and requiring clinical trial designs.
What kinds of teams are a good fit for this opportunity?
The opportunity is designed for teams that can bridge oncology, primary care, and health services research, build interventions that work at the level of practice workflows and health system operations, and test those interventions with rigorous evidence generation.
Browse more opportunities from the same category: Education, Health
Next opportunity: Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25 Clinical Trial Not Allowed)
Previous opportunity: IIJA Bureau of Land Management California Threatened and Endangered Species Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 23 025
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 23 025) also looked into and applied for these:
| Funding Opportunity |
|---|
| Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) Apply for PAR 23 125 Funding Number: PAR 23 125 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed) Apply for RFA CA 23 031 Funding Number: RFA CA 23 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional) Apply for PAR 23 122 Funding Number: PAR 23 122 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) Apply for PAR 23 269 Funding Number: PAR 23 269 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA CA 23 028 Funding Number: RFA CA 23 028 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) Apply for PAR 23 153 Funding Number: PAR 23 153 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) Apply for PAR 23 152 Funding Number: PAR 23 152 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Request for Applications (RFA): Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01, Clinical Trial Optional) Apply for RFA OD 23 015 Funding Number: RFA OD 23 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional) Apply for RFA CA 23 023 Funding Number: RFA CA 23 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) Apply for RFA CA 23 033 Funding Number: RFA CA 23 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed) Apply for RFA DE 24 001 Funding Number: RFA DE 24 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required) Apply for PAR 23 158 Funding Number: PAR 23 158 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 23 157 Funding Number: PAR 23 157 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) Apply for PAR 23 155 Funding Number: PAR 23 155 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed) Apply for RFA DA 24 020 Funding Number: RFA DA 24 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) Apply for RFA DA 24 038 Funding Number: RFA DA 24 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required) Apply for RFA DA 24 021 Funding Number: RFA DA 24 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) Apply for PAR 23 170 Funding Number: PAR 23 170 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Ending the HIV Epidemic: Resource Center to Engage Justice-Involved Populations (U24 Clinical Trial Optional) Apply for RFA DA 24 022 Funding Number: RFA DA 24 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Ending the HIV Epidemic: Focus on Justice Populations with SUD (R61/R33 Clinical Trial Required) Apply for RFA DA 24 015 Funding Number: RFA DA 24 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 23 025", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
